Synthesis, biological evaluation, molecular docking, and MD simulation of novel 2,4-disubstituted quinazoline derivatives as selective butyrylcholinesterase inhibitors and antioxidant agents

• Published in: Scientific reports 2024-07, Vol.14 (1), p.15577-14, Article 15577
• Main Authors: Sadeghian, Sara, Razmi, Raziyeh, Khabnadideh, Soghra, Khoshneviszadeh, Mehdi, Mardaneh, Pegah, Talashan, Arman, Pirouti, Arman, Khebre, Fatemeh, Zahmatkesh, Zahra, Rezaei, Zahra
• Format: Article
• Language: English
• Subjects: 631/154; 631/92; 692/699; Acetylcholinesterase; Acetylcholinesterase - chemistry; Acetylcholinesterase - metabolism; Alzheimer's disease; Animals; Antioxidant; Antioxidants; Antioxidants - chemical synthesis; Antioxidants - chemistry; Antioxidants - pharmacology; Butyrylcholinesterase - chemistry; Butyrylcholinesterase - metabolism; Catalytic Domain; Cholinesterase inhibitors; Cholinesterase Inhibitors - chemical synthesis; Cholinesterase Inhibitors - chemistry; Cholinesterase Inhibitors - pharmacology; Cognitive ability; Electrophorus; Enzymes; Humanities and Social Sciences; Humans; Inhibitors; Kinetics; MD simulation; Molecular docking; Molecular Docking Simulation; Molecular Dynamics Simulation; multidisciplinary; Neurodegenerative diseases; Quinazoline; Quinazolines - chemical synthesis; Quinazolines - chemistry; Quinazolines - pharmacology; Science; Science (multidisciplinary); Structure-Activity Relationship; Therapeutic targets
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-66424-z

Alzheimer’s disease is the most prevalent neurodegenerative disorder characterized by significant memory loss and cognitive impairments. Studies have shown that the expression level and activity of the butyrylcholinesterase enzyme increases significantly in the late stages of Alzheimer’s disease, so butyrylcholinesterase can be considered as a promising therapeutic target for potential Alzheimer’s treatments. In the present study, a novel series of 2,4-disubstituted quinazoline derivatives ( 6a – j ) were synthesized and evaluated for their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinestrase (BuChE) enzymes, as well as for their antioxidant activities. The biological evaluation revealed that compounds 6f , 6h , and 6j showed potent inhibitory activities against eqBuChE, with IC 50 values of 0.52, 6.74, and 3.65 µM, respectively. These potent compounds showed high selectivity for eqBuChE over eelAChE. The kinetic study demonstrated a mixed-type inhibition pattern for both enzymes, which revealed that the potent compounds might be able to bind to both the catalytic active site and peripheral anionic site of eelAChE and eqBuChE. In addition, molecular docking studies and molecular dynamic simulations indicated that potent compounds have favorable interactions with the active sites of BuChE. The antioxidant screening showed that compounds 6b , 6c , and 6j displayed superior scavenging capabilities compared to the other compounds. The obtained results suggest that compounds 6f, 6h, and 6j are promising lead compounds for the further development of new potent and selective BuChE inhibitors.